Release Date: January 19, 2015 | Expiration Date: January 19, 2016
Media: Print with online posttest, evaluation, and request for credit
The panel is structured using the Medical Crossfire platform, which is based on an engaging discussion among faculty that address treatment choices, provocative questions, and challenges in the clinic. This activity is designed to aid physicians in assessing the wealth of new data, choosing treatment based upon patient and tumor characteristics, and applying those findings to their practices.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists and hematologists who treat patients with melanoma. Fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers are also invited to participate.
After participating in this CME activity, learners should be better prepared to:
- Choose treatment based on patient characteristics, such as presence of brain metastases
- Manage toxicities of targeted and immune therapies
- Evaluate emerging clinical data regarding new agents and evolving strategies
Disclosure: No relevant financial relationships with commercial interests to disclose.
Debu Tripathy, MD
The American Journal of Hematology/Oncology® Editorial Board Member
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/Research Support: Genentech/Roche, Pfizer, Puma, Inc. (clinical trial support contracted to University of Southern California); Consultant: Eisai, Novartis
Adil I. Daud, MD
Clinical Professor of Medicine and Dermatology
Division of Hematology/ Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Disclosure: Grant/Research Support: Merck, Pfizer, GlaxoSmithKline, OncoSec, Novartis Pharmaceuticals, MedImmune, Genentech, Roche, and Bristol-Myers Squibb; Consultant: Genentech, Bristol-Myers Squibb, Amgen, and Celgene Corporation.
Ragini Kudchadkar, MD
Department of Hematology and Medical Oncology
Emory University Winship Cancer Institute
Disclosure: Consultant: Bristol-Myers Squibb, and Genentech; Speaker’s Bureau: Bristol-Myers Squibb, and Genentech.
Mario Sznol, MD
Professor of Medicine (Medical Oncology)
Yale School of Medicine
Clinical Research Program Leader, Melanoma Program
Co-Director of Yale SPORE in Skin Cancer
Yale Cancer Center
New Haven, CT
Disclosure: Consultant: Bristol-Myers Squibb, Genentech, Roche, MedImmune, Amgen, Nektar, Symphogen, Merus, NeoStem, Anaeropharma, BeiGene, Kyowa-Kirin, Immune Design, Lion Biotechnologies, Seattle Genetics, and Pfizer; Stock/Shareholder: Amphivena.
Jeffrey S. Weber, MD, PhD
Senior Member and Director
Donald A. Adam Comprehensive Melanoma Research Center
Moffitt Cancer Center
Disclosure: Grant/Research Support: Bristol-Myers Squibb, GlaxoSmithKline, Merck, Genentech, Novartis Pharmaceuticals, and Macrogenetics; Consultant: Bristol-Myers Squibb, GlaxoSmithKline, Merck, Genentech, Novartis Pharmaceuticals, AstraZeneca, cCAM Biotherapeutics, Celldex Therapeutics, Altor Bioscience, and Lion Biotechnologies.
The staff of PER® (Debbie Augustus, Ann C. Lichti, CCMEP and Megan O'Connell) as well as the editorial staff of The American Journal of Hematology/Oncology® (Devera Pine) have no relevant financial relationships with commercial interests to disclose.
Staff/Planner Disclosures and Conflict of Interest Resolution
In accordance with ACCME's Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is funded entirely by Physicians’ Education Resource®.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
Off-Label Disclosure and Disclaimer
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise